Skip to main content

Acurx Pharmaceuticals, Inc.

ACXP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001736243

No open-market purchases or sales by Acurx Pharmaceuticals, Inc. insiders were filed in the last 90 days; 18 institutions reported holding it in 13F filings for Q2 2026, worth $185.5K in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Acurx Pharmaceuticals, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ACXP: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders1318+5
Shares1.49M878.2K−606.8K (−40.9%)
Value$3.94M$1.32M−$2.62M (−66.5%)

New holders (7)

Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ACXP in Q3 2023
InstitutionSharesValue% of portfolio
Renaissance Technologies LLC18,800$28.0K0.00%
Citadel Advisors LLC18,841$26.9K0.00%
Morgan Stanley15,000$22.5K0.00%
Semmax Financial Advisors Inc.5,879$20.6K0.01%
Two Sigma Securities, LLC10,105$15.2K0.00%
Anchor Investment Management, LLC4,500$6.75K0.00%
Group One Trading, L.P.600$8580.00%

Sold out (2)

Institutions that held Acurx Pharmaceuticals, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of ACXP in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
One68 Global Capital, LLC13,044$34.6K
Salem Investment Counselors Inc100$265